Whitney T Carrico1, Gerald Georgette1, Michelle R Madore1, F Andrew Kozel1, Mark S George1, Steven Lindley1, Steven Lovett1, Jong H Yoon1, Jerome A Yesavage1. 1. is a Fellow in the Veterans Affairs (VA) War Related Injury and Illness Study Center; is a Clinical Research Nurse Coordinator; is Director of the VA National Clinical Repetitive Transcranial Magnetic Stimulation (TMS) Pilot Program; is an Attending Psychiatrist and Director of the Neuromodulation Clinic; is Director, Outpatient Mental Health; is Chief, Psychology Service; and is an Associate Chief of Staff for Mental Health and Director of the Mental Illness Education, Research and Clinical Centers; all at VA Palo Alto Health Care System in California. is Director of the TMS Clinic and a Staff Psychiatrist at James A. Haley Veterans Hospital; and a Professor, University of South Florida in Tampa. is a Distinguished University Professor of Psychiatry, Neurology and Radiology and Director of the Brain Stimulation Division, Medical University of South Carolina, and a Staff Psychiatrist and Director of the TMS Clinic at Ralph H. Johnson VA Medical Center in Charleston. Steven Lindley and Jong Yoon are Associate Professors of Psychiatry; and Jerome Yesavage is an Associate Chair of Psychiatry and Behavioral Sciences and Professor of Neurology and Neurological Sciences (by courtesy); all at Stanford University School of Medicine in Palo Alto.
Abstract
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) uses a device to create magnetic fields that cause electrical current to flow into targeted neurons in the brain. The most common clinical use of rTMS is for the treatment of major depressive disorder (MDD). The annual suicide rate of veterans has been higher than the national average; treating depression with rTMS would likely decrease suicide risk. MDD in many patients can be chronic and reoccurring with medication and psychotherapy providing inadequate relief. METHODS: A pilot program was created to supply rTMS devices to 35 different sites in the VA nationwide in order to treat treatment-resistant depression. CONCLUSIONS: At time of analysis more than 950 veterans have started the program and 412 have finished. Nationwide, we have seen the depression scores decline, indicating an improvement in well-being. In addition, there is high patient satisfaction. Collecting data on a national level is a powerful way to examine rTMS efficacy and predictors of response which might be lost on a smaller subset of cases.
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) uses a device to create magnetic fields that cause electrical current to flow into targeted neurons in the brain. The most common clinical use of rTMS is for the treatment of major depressive disorder (MDD). The annual suicide rate of veterans has been higher than the national average; treating depression with rTMS would likely decrease suicide risk. MDD in many patients can be chronic and reoccurring with medication and psychotherapy providing inadequate relief. METHODS: A pilot program was created to supply rTMS devices to 35 different sites in the VA nationwide in order to treat treatment-resistant depression. CONCLUSIONS: At time of analysis more than 950 veterans have started the program and 412 have finished. Nationwide, we have seen the depression scores decline, indicating an improvement in well-being. In addition, there is high patient satisfaction. Collecting data on a national level is a powerful way to examine rTMS efficacy and predictors of response which might be lost on a smaller subset of cases.
Authors: Jerome A Yesavage; J Kaci Fairchild; Zhibao Mi; Kousick Biswas; Anne Davis-Karim; Ciaran S Phibbs; Steven D Forman; Michael Thase; Leanne M Williams; Amit Etkin; Ruth O'Hara; Gerald Georgette; Tamara Beale; Grant D Huang; Art Noda; Mark S George Journal: JAMA Psychiatry Date: 2018-09-01 Impact factor: 21.596
Authors: Martin Tik; André Hoffmann; Ronald Sladky; Livia Tomova; Allan Hummer; Lucia Navarro de Lara; Henryk Bukowski; Jürgen Pripfl; Bharat Biswal; Claus Lamm; Christian Windischberger Journal: Neuroimage Date: 2017-09-12 Impact factor: 6.556
Authors: F Andrew Kozel; Michael Hernandez; Kimberly Van Trees; Sean Phillips; Jaffrey Hashimie; Mark Weisman; Demian Obregon; Deborah L Sanchez; Glenn Catalano; Susan K Schultz Journal: Ann Clin Psychiatry Date: 2017-11 Impact factor: 1.567
Authors: F Andrew Kozel; Kimberly Van Trees; Valerie Larson; Sean Phillips; Jaffrey Hashimie; Brian Gadbois; Suzanne Johnson; Jessica Gallinati; Blake Barrett; Peter Toyinbo; Mark Weisman; Michael Centorino; Carri-Ann Gibson; Glenn Catalano Journal: Psychiatry Res Date: 2019-01-03 Impact factor: 3.222
Authors: Sarah H Lisanby; Mustafa M Husain; Peter B Rosenquist; Daniel Maixner; Rosben Gutierrez; Andrew Krystal; William Gilmer; Lauren B Marangell; Scott Aaronson; Zafiris J Daskalakis; Randolph Canterbury; Elliott Richelson; Harold A Sackeim; Mark S George Journal: Neuropsychopharmacology Date: 2008-08-13 Impact factor: 7.853
Authors: Tarique Perera; Mark S George; Geoffrey Grammer; Philip G Janicak; Alvaro Pascual-Leone; Theodore S Wirecki Journal: Brain Stimul Date: 2016-03-16 Impact factor: 8.955
Authors: M S George; E M Wassermann; W A Williams; A Callahan; T A Ketter; P Basser; M Hallett; R M Post Journal: Neuroreport Date: 1995-10-02 Impact factor: 1.837
Authors: A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Jonathan W Stewart; Andrew A Nierenberg; Michael E Thase; Louise Ritz; Melanie M Biggs; Diane Warden; James F Luther; Kathy Shores-Wilson; George Niederehe; Maurizio Fava Journal: N Engl J Med Date: 2006-03-23 Impact factor: 91.245
Authors: Michelle R Madore; F Andrew Kozel; Leanne M Williams; L Chauncey Green; Mark S George; Paul E Holtzheimer; Jerome A Yesavage; Noah S Philip Journal: J Affect Disord Date: 2021-10-20 Impact factor: 4.839